Happy to share that our project on the role of galectins in immune evasion has been awarded 6 MSEK in funding from the ErlingPersson Foundation. Grateful to the entire lab team and to the foundation for their support!
Back home from the Swedish Cancer Research Meeting in Malmö. Great meeting! Great contributions from our lab by Parniyan och Cedric!
Currently looking for a post-doc!
umustipendie.varbi.com/en/?j…
New paper published from our lab! Characterization of a new interferon-response CAFs with tumor-restraining properties.
aacrjournals.org/cancerres/a…
Daniel Öhlund retweeted
Nature research paper: MYC ecDNA promotes intratumour heterogeneity and plasticity in PDAC
go.nature.com/3XPqIz1
Currently looking for a post-doc!
umustipendie.varbi.com/en/wh…
Daniel Öhlund retweeted
🧵1/ Excited to share our latest review on how organoid technology is transforming pancreatic cancer research, published in Experimental & Molecular Medicine. Here's a breakdown of the key points. nature.com/articles/s12276-0…
Daniel Öhlund retweeted
🔥🔥 new day, 🆕 #pancreas2000 project 📣🤩
Pooled OR for pancreatic steatosis (PS) in patients with PDAC vs. controls was 3.23 (95% CI 1.86-5.60).
⬇️ ⬇️
tinyurl.com/fatpanc
We need to prioritize a standardized approach to the diagnosis, follow-up, and treatment of PS.
Daniel Öhlund retweeted
Some highlights from the Botton-Champalimaud conference. Especially happy to see @vincorbo and @DanielOhlund continuing doing fab science. Nothing makes me happier than seeing good humans doing great.
💜💪🏻🌟
Our new review paper is out!
Overcoming therapy resistance in pancreatic cancer: New insights and future directions
doi.org/10.1016/j.bcp.2024.1…
The results from the NORPACT-1 trial are out! Conclusion: no survival benefit from neoadjuvant FOLFIRINOX in resectable pancreatic ductal adenocarcinoma compared with upfront surgery thelancet.com/journals/langa…
Daniel Öhlund retweeted
Maréne Landström, Institutionen för medicinsk biovetenskap, har utsetts till Årets cancerforskare av Cancerfondens forskningsnämnd. Det är främst upptäckten av specialiserade antikroppar, som kan förhindra att prostatacancer sprider sig, som uppmärksammas. umu.se/nyheter/umeaforskare-…
I’m looking for a postdoc to the lab!
umu.se/en/work-with-us/postd… – at Umeå, Sverige
Congratulations to Joshua Cumming! PhD defence @UmeaUniversity yesterday. Great discussion with opponent @claus_jorgensen. – at Umeå, Sverige
Daniel Öhlund retweeted
🔥NORPACT-1: Short-course neoadjuvant FOLFIRINOX vs surgery + adj. therapy for #PDAC #ASCO23
🔎12 Nordic centers, phs-2, 140 pts
👉52% completed neoadj. CTx
🤨mOS: 25.1 mo vs 38.5 mo
✅manageable safety, but no benefit of neoadj. FOLFIRINOX
@myESMO @OncoAlert
Daniel Öhlund retweeted
Jag är mycket hedrad över detta uppdrag 🙏🏻! Tack till @Cancerfonden och min företrädare professor Klas Kärre! ”Standing on the shoulders of giants”
Vi är otroligt glada över att välkomna professor @MalinASund som ny ordförande för vår forskningsnämnd. Nämnden bedömer och beslutar om vilka forskningsprojekt som ska få medel från oss vilket under 2022 handlade om 900 miljoner kronor. @umeauniversitet
Daniel Öhlund retweeted
Today is #DNADay commemorating 70 years since “Molecular Structure of Nucleic Acids: A Structure for Deoxyribose Nucleic Acid” was published & 20 years since the completion of the Human Genome Project.
Let’s take a historical look back...🧬
dnascience.plos.org/2023/04/…
Daniel Öhlund retweeted
Bench mate reunion at #GRCpancreas in Lucca Italy @DanielOhlund
Daniel Öhlund retweeted
Carl Kempe, hedersdoktor vid Umeå universitet och ständig sekreterare för Kempestiftelserna, har gått bort 84 år gammal. Hans engagemang har bidragit till att betydande finansiellt stöd givits till forskning och forskare på olika sätt. 🌹 Minnestext: umu.se/nyheter/carl-kempe-in…


























